Phase 1, Open-label, Two-Cohort Study of Orally Administered PAX-1 in Patients with Moderate COVID-19
A Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase II Study to Assess the Opioid-Sparing Activity of PAX-1 in Patients with Persistent Cancer Pain.
100 项与 Komipharm International Australia Pty Ltd. 相关的临床结果
0 项与 Komipharm International Australia Pty Ltd. 相关的专利(医药)
100 项与 Komipharm International Australia Pty Ltd. 相关的药物交易
100 项与 Komipharm International Australia Pty Ltd. 相关的转化医学